<DOC>
	<DOCNO>NCT02423512</DOCNO>
	<brief_summary>Vedolizumab new medication use treatment Crohn 's disease Ulcerative colitis . It work block specific white blood cell ( alpha 4-beta7 lymphocyte ) migrate area inflammation gastrointestinal tract . Previous study show patient previous exposure another type medication Crohn 's disease Ulcerative colitis ( anti-TNF medication ) respond vedolizumab well never expose . This study investigate biologic marker blood tissue help identify possible reason difference .</brief_summary>
	<brief_title>The Impact Anti-TNF Exposure Vedolizumab Effectiveness</brief_title>
	<detailed_description>Patients enrol study select initiate vedolizumab therapy . Vedolizumab intravenous infusion give increase interval . The first infusion vedolizumab consider baseline . Patients may enrol baseline colonoscopy prior first schedule infusion vedolizumab ( pre-treatment visit ) . The standard induction protocol vedolizumab consist infusion week 0 ( baseline ) , week 2 , week 6 . Vedolizumab , per standard-of-care , continue interval every 8 week follow induction therapy . Vedolizumab treatment prescribe per standard practice prescribe regardless participation study . Patients receive medication sole purpose research . Treatment decision include timing wash period anti-TNf vedolizumab make subject 's physician per research protocol . There protocolized washout period patient previously receive anti-TNF therapy treatment standard care per direct physician . Standard care laboratory test perform clinical laboratory Mount Sinai Hospital . All measurement complete Prometheus Therapeutics &amp; Diagnostics San Diego , California Takeda identify lab vedolizumab concentration antibody .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Vedolizumab</mesh_term>
	<criteria>Male female adult diagnosis inflammatory bowel disease Patients start vedolizumab therapy clinically indicated discussion treat physician eligible . Patients start vedolizumab sole purpose study Patients prior exposure vedolizumab natalizumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Inflammatory Bowel Diseases</keyword>
	<keyword>Vedolizumab</keyword>
	<keyword>Ulcerative Colitis</keyword>
	<keyword>Crohn 's Disease</keyword>
	<keyword>MADCAM1</keyword>
	<keyword>integrin alpha4beta7</keyword>
</DOC>